What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson cardiovascular short-peptide bioregulator
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Cardiogen inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Cardiogen is a Khavinson-class short-peptide bioregulator positioned as the cardiovascular-tissue member of the Khavinson short-peptide framework. Like the other Khavinson products, Cardiogen is hypothesized to act as an endogenous bioregulator of gene-expression programs in its target tissue (cardiomyocytes and cardiovascular tissue), supporting cell-cycle balance and tissue maintenance under stress. The molecule appears in the Russian and Eastern European research literature as part of the broader Khavinson bioregulator class but does not carry a single defined sequence in all sources, buyers should treat Cardiogen as a class designation requiring batch-specific identity confirmation rather than a single defined molecule. PeptideXpo supplies Cardiogen as a lyophilized 20 mg vial at ≥99.0% HPLC purity. As with the rest of the Khavinson class, CAS is not consistently registered and identity must be established via sequence verification on the batch COA. Buyers conducting research-protocol work involving Cardiogen should request the exact sequence on the COA and confirm it matches the published reference they are working from.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm sequence and identity per batch COA.
Frequently asked questions
Cardiogen is positioned within the Khavinson short-peptide bioregulator framework as the cardiovascular-tissue regulatory peptide, but the published clinical evidence is concentrated in Russian and Eastern European journals with limited Western peer-reviewed coverage. The Russian-school literature reports cardiovascular-protective effects in animal models and small clinical cohorts, but the methodology and statistical power of these studies don't meet the rigor standards of Western evidence-based-medicine frameworks. Buyers conducting Cardiogen research should reference the original Khavinson-school publications for protocol design and treat the molecule as an investigational research tool rather than a clinically-validated cardiovascular agent.
Cardiogen and Vesugen are positioned as complementary cardiovascular-tissue regulatory peptides within the broader Khavinson framework. Cardiogen targets cardiomyocyte and myocardial-tissue gene-expression programs; Vesugen (KED tripeptide) targets vascular endothelial gene-expression. The two peptides are sometimes combined in cardiovascular-research protocols on the rationale that comprehensive cardiovascular effects involve both myocardium and vasculature. As with all Khavinson-class products, the comparative pharmacology is concentrated in the Russian-school literature and the mechanistic distinction between the two peptides isn't supported by independent Western data. Buyers conducting comparative research should source both products and reference the original Khavinson publications for protocol design specifics.
Unlike the well-characterized tetrapeptide members of the Khavinson family (Epitalon AEDG, Bronchogen AEDL, Cortagen AEDP), Cardiogen's exact peptide sequence is not consistently published in primary Khavinson-school sources, and different upstream suppliers may produce somewhat different preparations under the Cardiogen brand name. Some sources describe Cardiogen as a tetrapeptide; others position it as a small mixture of cardiovascular-targeting short peptides. The sequence ambiguity is the primary reason CAS is not registered and why batch-COA sequence-verification is essential before any research use, buyers should request the explicit sequence on the released batch documentation and treat Cardiogen as a defined product only after that confirmation.
Related peptides
4-mer
Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
3-mer
Khavinson vascular tripeptide (Lys-Glu-Asp, KED)
